Article
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2011
Faratian Dana, Zweemer Annelien J M, Nagumo Yoko, Sims Andrew H, Muir Morwenna, Dodds Michael, Mullen Peter, Um Inhwa, Kay Charlene, Hasmann Max, Harrison David J, Langdon Simon P
Abstract excerpt
PURPOSE: The aim of this study was to investigate the antitumor effects of HER2-directed combination therapy in ovarian cancer xenograft models to evaluate their potential. The combinations of trastuzumab and pertuzumab, and trastuzumab and aromatase inhibitor therapy were investigated. EXPERIMEN...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.